Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.9K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.9K
Schemas01:42

Schemas

12.3K
A schema is a mental construct consisting of a cluster or collection of related concepts (Bartlett, 1932). There are many different types of schemata, and they all have one thing in common: schemata are a method of organizing information that allows the brain to work more efficiently. When a schema is activated, the brain makes immediate assumptions about the person or object being observed.
12.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Route of Allergen Immunotherapy: A Global Look Into Physicians' Motivations.

Allergy·2026
Same author

Why physicians underuse patient-reported outcomes in atopic dermatitis and chronic urticaria - Insights from the UCARE/ADCARE PROMUSE study.

The World Allergy Organization journal·2026
Same author

Estimating work-related indirect costs in allergic rhinitis and asthma using a daily combined symptom-medication score: a MASK-air® study in collaboration with the EAACI Methodology Committee.

The journal of allergy and clinical immunology. In practice·2026
Same author

Clinical outcomes and remission trajectories in obese and non-obese patients with severe asthma treated with biologics: a retrospective longitudinal cohort study from the Severe Asthma Network Italy (SANI) registry.

The Lancet regional health. Europe·2026
Same author

From mild-to-moderate to severe asthma: Risk factors and patient profiles from the NORDSTAR cohort.

American journal of respiratory and critical care medicine·2026
Same author

Trace Elements in Allergy: Narrative Review.

Allergy·2026
Same journal

Diagnostic Performance of Skin Prick Test and Specific Immunoglobulin E in Children Sensitized to Cat Allergen.

International archives of allergy and immunology·2026
Same journal

Differences in Reported Anaphylaxis Associated With Common Nonsteroidal Anti-inflammatory Drugs: A Pharmacovigilance Study.

International archives of allergy and immunology·2026
Same journal

Association of Serum Galectin-3 Binding Protein with Acute Exacerbation, Inflammation, and Airway Remodeling in Pediatric Asthma.

International archives of allergy and immunology·2026
Same journal

Effectiveness of a Provincial Law to Improve Epinephrine Use for Anaphylaxis in Schools in Alberta, Canada: A Pre-Post Study.

International archives of allergy and immunology·2026
Same journal

Rab27 a regulates dendritic cell immune tolerogenic capacity.

International archives of allergy and immunology·2026
Same journal

Burden of Hereditary Angioedema in Adults: Impact of Disease and Patient Characteristics.

International archives of allergy and immunology·2026
See all related articles

Related Experiment Video

Updated: Feb 3, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.0K

Intralymphatic Immunotherapy: Update and Unmet Needs.

Gabriela Senti1, Andreas U Freiburghaus2, Désirée Larenas-Linnemann3

  • 1Clinical Trials Center, University Hospital Zurich, Zurich, Switzerland, gabriela.senti@usz.ch.

International Archives of Allergy and Immunology
|November 5, 2018
PubMed
Summary
This summary is machine-generated.

Intralymphatic immunotherapy (ILIT) offers a promising, short-duration allergy treatment with low allergen doses. Clinical results are encouraging, but further research is needed to optimize this novel approach.

Keywords:
Allergen-specific immunotherapyAllergyClinical trialsIntralymphatic immunotherapy

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.6K

Related Experiment Videos

Last Updated: Feb 3, 2026

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

17.6K

Area of Science:

  • Immunology
  • Allergy Research
  • Clinical Trials

Background:

  • Allergen-specific immunotherapy (AIT) is the sole allergy treatment providing long-term symptom relief.
  • Current AIT methods include subcutaneous injection (SCIT), sublingual (SLIT), and oral immunotherapy (OIT).
  • Intralymphatic immunotherapy (ILIT) presents a novel application route for AIT.

Purpose of the Study:

  • To review the clinical evidence for intralymphatic immunotherapy (ILIT).
  • To compare ILIT with existing AIT methods.
  • To highlight the potential advantages and limitations of ILIT.

Main Methods:

  • Review of up-to-date clinical evidence for ILIT.
  • Focus on ultrasound-guided intralymphatic injections into inguinal lymph nodes.
  • Comparison of ILIT treatment duration and allergen dosage with SCIT, SLIT, and OIT.

Main Results:

  • ILIT demonstrates major advantages in treatment duration and low allergen doses.
  • The complete ILIT regimen involves only three injections spaced one month apart.
  • Early clinical results for ILIT are encouraging, despite limited patient numbers in randomized controlled trials.

Conclusions:

  • ILIT shows significant promise as a novel AIT approach.
  • Further clinical trials are essential to validate ILIT's efficacy and safety.
  • Additional preclinical research is required to optimize ILIT formulations.